Biosimilar Promising for Treatment of ERBB2+ Breast Cancer
Equivalent response rate for women with ERBB2-positive metastatic breast cancer receiving taxanes
ER-Positive Breast Cancer
Preventative therapies for healthy women at high risk of breast cancer
SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.
Drug resistance reversed when tamoxifen is paired with antimalarial agent
The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.
Treating breast cancer drug resistance via a malaria drug
An inexpensive malaria drug could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study.
ASCO: Obesity and ER+ breast cancer mortality link limited to pre-menopause
In estrogen receptor (ER)+ breast cancer, obesity is positively associated with breast cancer mortality only among pre-/peri-menopausal women, according to new research.
Smoking increases ER-positive breast cancer risk for women
Younger women who smoke appear to be at increased risk for developing ER-positive breast cancer, according to research, but no association found for risk of triple-negative breast cancer.
Models of drug-resistant breast cancer suggest better treatments
Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research presented at the 2013 San Antonio Breast Cancer Symposium.
New driver of breast cancer discovered
As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
Resistance to breast cancer treatment tied to mutations in estrogen receptor
A type of mutation that develops after breast cancer patients take antiestrogen therapies has been identified. These mutations help to explain why patients often become resistant to these types of therapies.
Biomarker based on gene expression predicts long-term risk for breast cancer recurrence
The breast cancer index (BCI) was the only one of three methods compared that predicted the risk for recurrence in women treated for estrogen-receptor (ER)-positive breast cancer.
- Loading...
Loading...
Loading... 
Loading...